Santen CEO's Clear Vision For World 'Built On Ability To See'

Ex-Japan Markets To Drive Growth

09 Mar 2022

CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview.

Santen President And CEO Shigeo Taniuchi • Source: Santen

When asked to sum up what Santen Pharmaceutical Co., Ltd. sees as its broad health mission, the Japanese ophthalmology company’s president and CEO does not hesitate.

“There is a global focus on eye health given the impact of disease on fundamental activities such as education and employment

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

13 May 2025

• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

12 May 2025

• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

12 May 2025

• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.